Ultraviolet A1 phototherapy: A British Photodermatology Group workshop report

Clinical and Experimental Dermatology

Volumn 37, Issue 3, 2012, Pages 219-226

  Kerr, A C ^a   Ferguson, J ^a   Attili, S K ^a   Beattie, P E ^b   Coleman, A J ^c   Dawe, R S ^a   Eberlein, B ^d   Goulden, V ^e   Ibbotson, S H ^a   Menage, H Du P ^c   Moseley, H ^a   Novakovic, L ^c   Walker, S L ^c   Woods, J A ^a   Young, A R ^c   Sarkany, R P E ^c  

^a NINEWELLS HOSPITAL   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOPIC DERMATITIS; CHRONIC URTICARIA; CUTANEOUS T CELL LYMPHOMA; ERYTHEMA; GRAFT VERSUS HOST REACTION; GRANULOMA ANNULARE; HAND ECZEMA; HUMAN; HYPEREOSINOPHILIC SYNDROME; LICHEN SCLEROSUS ET ATROPHICUS; LOCALIZED SCLERODERMA; MONOTHERAPY; NEPHROGENIC SYSTEMIC FIBROSIS; PHOTOTHERAPY; PITYRIASIS LICHENOIDES; PITYRIASIS RUBRA PILARIS; PRIORITY JOURNAL; PSORIASIS; PUVA; REVIEW; SARCOIDOSIS; SKIN INFLAMMATION; SKIN PIGMENTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TERTIARY HEALTH CARE; ULTRAVIOLET A RADIATION; UNITED KINGDOM; URTICARIA PIGMENTOSA; WORKSHOP;

GREAT BRITAIN; HEALTH SERVICES ACCESSIBILITY; HUMANS; SKIN DISEASES; ULTRAVIOLET THERAPY;

EID: 84858440902     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2011.04256.x     Document Type: Review

References (30)

1. Mutzhas MF, Holzle E, Hofmann C, et al. A new apparatus with high radiation energy between 320 and 460 nm: physical description and dermatological applications. J Invest Dermatol 1981; 76: 42-7. (Pubitemid 11173536)
2. Edstrom DW, Porwit A, Ros AM,. Effects on human skin of repetitive ultraviolet-A1 (UVA1) irradiation and visible light. Photodermatol Photoimmunol Photomed 2001; 17: 66-70. (Pubitemid 32284908)
3. Kielbassa C, Roza L, Epe B,. Wavelength dependence of oxidative DNA damage induced by UV and visible light. Carcinogenesis 1997; 18: 811-16. (Pubitemid 28132472)
4. Ravanat JL, Douki T, Cadet J,. Direct and indirect effects of UV radiation on DNA and its components. J Photochem Photobiol B 2001; 63: 88-102. (Pubitemid 33040727)
5. Mouret S, Philippe C, Gracia-Chantegrel J, et al. UVA-induced cyclobutane pyrimidine dimers in DNA: a direct photochemical mechanism? Org Biomol Chem 2010; 8: 1706-11.
6. Yamauchi R, Morita A, Yasuda Y, et al. Different susceptibility of malignant versus nonmalignant human T cells toward ultraviolet A-1 radiation-induced apoptosis. J Invest Dermatol 2004; 122: 477-83. (Pubitemid 38281072)
7. Gruss C, Reed JA, Altmeyer P, et al. Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet 1997; 350: 1295-6. (Pubitemid 28036641)
8. Petersen MJ, Hansen C, Craig S,. Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol 1992; 99: 440-4.
9. Kroft EB, Berkhof NJ, van de Kerkhof PC, et al. Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol 2008; 59: 1017-30.
10. Dawe RS,. Ultraviolet A1 phototherapy. Br J Dermatol 2003; 148: 626-37. (Pubitemid 36629739)
11. Breuckmann F, Gambichler T, Altmeyer P, et al. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatol 2004; 4: 11.
12. Legat FJ, Hofer A, Brabek E, et al. Narrowband UV-B vs medium-dose UV-A1 phototherapy in chronic atopic dermatitis. Arch Dermatol 2003; 139: 223-4. (Pubitemid 36216265)
13. Majoie IM, Oldhoff JM, van Weelden H, et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2009; 60: 77-84.
14. Tzaneva S, Kittler H, Holzer G, et al. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol 2010; 162: 655-60.
15. Krutmann J, Diepgen TL, Luger TA, et al. High-dose UVA1 therapy for atopic dermatitis. results of a multicenter trial. J Am Acad Dermatol 1998; 38: 589-93. (Pubitemid 28182930)
16. Krutmann J, Czech W, Diepgen T, et al. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 1992; 26: 225-30.
17. von Kobyletzki G, Pieck C, Hoffmann K, et al. Medium-dose UVA1 cold-light phototherapy in the treatment of severe atopic dermatitis. J Am Acad Dermatol 1999; 41: 931-7.
18. Kowalzick L, Kleinheinz A, Weichenthal M, et al. Low dose versus medium dose UV-A1 treatment in severe atopic eczema. Acta Derm Venereol 1995; 75: 43-5.
19. Dittmar HC, Pflieger D, Schopf E, et al. [UVA1 phototherapy. Pilot study of dose finding in acute exacerbated atopic dermatitis] (in German). Hautarzt 2001; 52: 423-7. (Pubitemid 32463562)
20. Tzaneva S, Seeber A, Schwaiger M, et al. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol 2001; 45: 503-7. (Pubitemid 32917242)
21. Jekler J, Larko O,. Phototherapy for atopic dermatitis with ultraviolet A (UVA), low-dose UVB and combined UVA and UVB two paired-comparison studies. Photodermatol Photoimmunol Photomed 1991; 8: 151-6.
22. Kroft EB, van de Kerkhof PC, Gerritsen MJ, et al. Period of remission after treatment with UVA-1 in sclerodermic skin diseases. J Eur Acad Dermatol Venereol 2008; 22: 839-44. (Pubitemid 351850083)
23. Kreuter A, Hyun J, Stucker M, et al. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006; 54: 440-7. (Pubitemid 43243447)
24. Beattie PE, Dawe RS, Traynor NJ, et al. Can St John's wort (hypericin) ingestion enhance the erythemal response during high-dose ultraviolet A1 therapy? Br J Dermatol 2005; 153: 1187-91. (Pubitemid 41779575)
25. Beattie PE, Wilkie MJ, Smith G, et al. Can dietary furanocoumarin ingestion enhance the erythemal response during high-dose UVA1 therapy? J Am Acad Dermatol 2007; 56: 84-7. (Pubitemid 46016998)
26. Rombold S, Lobisch K, Katzer K, et al. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed 2008; 24: 19-23.
27. Tuchinda C, Kerr HA, Taylor CR, et al. UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States. Photodermatol Photoimmunol Photomed 2006; 22: 247-53. (Pubitemid 44317158)
28. Jacobe HT, Cayce R, Nguyen J,. UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I-V. Br J Dermatol 2008; 159: 691-6.
29. Wallenfang K, Stadler R,. [Association between UVA1 and PUVA bath therapy and development of malignant melanoma] (in German). Hautarzt 2001; 52: 705-7. (Pubitemid 32757702)
30. Dawe RS,. There are no 'safe exposure limits' for phototherapy. Br J Dermatol 2010; 163: 209-10.